MAM
CTIC

Meeder Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Meeder Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,410
Closed -$1K – 1999
2018
Q4 		$1K Sell
1,410
-677
-32% -$1.11K ﹤0.01% 1692
2018
Q3 		$5K Buy
+2,087
New +$5.17K ﹤0.01% 1355

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Meeder Asset Management's CTIC Position: Q1 2019 in Review

Meeder Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2019, closing a stake of 1,410 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in CTIC in Q3 2018 and held it in 2 quarters. The position peaked at $5K in Q3 2018. 67 funds tracked by Wall St. Rank hold CTIC as of Q1 2019.

  • Meeder Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2019 after selling out during the quarter.
  • Meeder Asset Management sold 1,410 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2019, an estimated $1K.
  • Meeder Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2018 and held it in 2 quarters.
  • Meeder Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $5K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.